Cargando…

Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib

Detalles Bibliográficos
Autores principales:	Telang, Sucheta, O’Neal, Julie, Tapolsky, Gilles, Clem, Brian, Kerr, Alan, Imbert-Ferndandez, Yoannis, Chesney, Jason
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072985/ http://dx.doi.org/10.1186/2049-3002-2-S1-P14

Ejemplares similares

Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism
por: Klarer, Alden C, et al.
Publicado: (2014)

Simultaneous inhibition of the estrogen receptor and 6-phosphofructo-2-kinase (PFKFB3) for the treatment of ER+ breast cancer
por: Imbert-Fernandez, Yoannis, et al.
Publicado: (2014)

Fructose-2,6-bisphosphate links glucose to survival and growth
por: Yalcin, Abdullah, et al.
Publicado: (2014)

Fructose-2,6-Bisphosphate synthesis by 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth
por: Chesney, Jason, et al.
Publicado: (2014)

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors
por: Chesney, Jason, et al.
Publicado: (2018)

6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27
por: Yalcin, A, et al.
Publicado: (2014)

Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
por: Mondal, Susmita, et al.
Publicado: (2018)

Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor
por: Chesney, Jason, et al.
Publicado: (2015)

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs
por: Lypova, Nadiia, et al.
Publicado: (2021)

The kinase domain of PFKFB4 is required to stimulate the glucose metabolism and growth of H460 xenografts
por: Clark, J, et al.
Publicado: (2014)

Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth
por: Telang, Sucheta, et al.
Publicado: (2012)

B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells
por: Roos, Wynand P., et al.
Publicado: (2014)

Virus detection and identification using random multiplex (RT)-PCR with 3'-locked random primers
por: Clem, Amy L, et al.
Publicado: (2007)

Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation
por: Telang, Sucheta, et al.
Publicado: (2012)

Metabolic imaging using hyperpolarized (13)C‐pyruvate to assess sensitivity to the B‐Raf inhibitor vemurafenib in melanoma cells and xenografts
por: Acciardo, Stefania, et al.
Publicado: (2019)

A Novel Small Molecule Antagonist of Choline Kinase-α That Simultaneously Suppresses MAPK and PI3K/AKT Signaling
por: Clem, Brian F., et al.
Publicado: (2011)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

Resistance to RAF inhibitors revisited
por: Hartsough, Edward, et al.
Publicado: (2013)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
por: Żołek, Teresa, et al.
Publicado: (2023)

Mechanisms of resistance to RAF inhibitors in melanoma
por: Aplin, Andrew E., et al.
Publicado: (2011)

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells
por: Shingu, Takashi, et al.
Publicado: (2016)

Inhibition of AMPK/PFKFB3 mediated glycolysis synergizes with penfluridol to suppress gallbladder cancer growth
por: Hu, Jiahao, et al.
Publicado: (2022)

Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics
por: Grahovac, Jelena, et al.
Publicado: (2019)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

The PFKFB3 Inhibitor AZ67 Inhibits Angiogenesis Independently of Glycolysis Inhibition
por: Emini Veseli, Besa, et al.
Publicado: (2021)

Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
por: Sondermann, Wiebke, et al.
Publicado: (2015)

Dupuytren’s contractures associated with the BRAF inhibitor vemurafenib: a case report
por: Chan, Sze Wai, et al.
Publicado: (2015)

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
por: Aylwin, Simon J. B., et al.
Publicado: (2015)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
por: Marusiak, Anna A., et al.
Publicado: (2014)

B-Raf and the inhibitors: from bench to bedside
por: Huang, Tiangui, et al.
Publicado: (2013)

RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
por: Zebisch, Armin, et al.
Publicado: (2019)

Targeting aspartate aminotransferase in breast cancer
por: Thornburg, Joshua Marshall, et al.
Publicado: (2008)

Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq
por: Lanceta, Lilibeth, et al.
Publicado: (2021)

Discovery of New Quinolone-Based Diarylamides as Potent B-RAF(V600E)/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity
por: Kim, Hyun Ji, et al.
Publicado: (2023)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib
por: Tkacik, Emre, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7shkou4oa40to9ge8tr2fn156k